Default Category
-
Cipla (Spanish version)
Deshpande, Rohit; Winig, LauraCase HBS-520S15MarketingThe head of Cipla, a $325-million-dollar Indian pharmaceutical company and seller of low-cost AIDS drugs to South Africa, must decide what to do about Cipla's future. With India poised to enforce international patents in only two years, much of Cipla's product line could become unsaleable (given that it is based on product patents protected in industrialized countries). Describes Cipla's role in forcing global pharmaceutical companies to lower th...Starting at €8.20
-
Cipla 2011 (Spanish version)
Deshpande, Rohit; Sucher, Sandra J.; Winig, LauraCase HBS-517S04Business Ethics and Corporate Social ResponsibilityDr. Yusuf Hamied, head of the Indian pharma and generics manufacturing company Cipla, is weighing options for how to continue to support the global fight against HIV/AIDS while positioning his company for growth in a changing regulatory landscape.Starting at €8.20
-
Building Brand Infosys
Deshpande, Rohit; Muthuram, VidhyaCase HBS-513003-EMarketingInfosys Limited was India's second largest exporter of IT services with annual revenues of $7 billion and a market capitalization of nearly $26 billion in 2012. The company, headquartered in Bangalore, India, had built its reputation as the Indian IT bellwether whose credo was to "under-promise and over-deliver." Throughout its 31-year history, Infosys and its iconic co-founder, N.R. Narayana Murthy, were admired and respected for delivering exce...Starting at €8.20
-
Serum Institute of India (SII) : Racing to Save Lives During a Pandemic
Deshpande, Rohit; Raina, Anjali; Chawla, RachnaCase HBS-521028-EBusiness Ethics and Corporate Social ResponsibilityThe CEO of Serum Institute of India (SII), a $12.8 billion Indian Family business is faced with a risky choice between principles and profit. SII is the largest manufacturer of vaccines in the world and Adar Poonawalla, the CEO and son of the founder has to decide how to temper his responsibility to meet the world's need for an affordable, efficacious and safe COVID-19 vaccine with his need to maintain profitability.Starting at €8.20